[Immune System in Patients with Head and Neck Carcinoma]

Area of Science:

• Oncology
• Immunology
• Virology

Context:

• Head and neck squamous cell carcinoma (HNSCC) risk factors include tobacco, alcohol, and human papillomavirus (HPV).
• HPV is a significant risk factor, especially for oropharyngeal carcinoma.
• HPV-positive HNSCC exhibits a distinct biological profile and better prognosis compared to HPV-negative HNSCC.

Purpose:

• To review the current understanding of antitumor immune responses in HPV-positive versus HPV-negative HNSCC.
• To explore the factors contributing to the better prognosis of HPV-positive HNSCC.
• To discuss the role of HPV-specific immunity in therapeutic responses and emerging immunotherapy approaches.

Summary:

• HPV-positive HNSCC tumors show a robust infiltration of HPV-specific T-cells, suggesting an active immune response.
• Despite immune presence, tumor development can occur due to antigen processing defects, T-cell dysfunction, or immunosuppressive cells.
• The immunologic profile of HPV-positive HNSCC is associated with better outcomes, with HPV-specific immunity playing a crucial role in treatment response.

Impact:

• Highlights the critical role of the immune system in HNSCC prognosis and treatment.
• Provides insights into the differences between HPV-positive and HPV-negative HNSCC, informing targeted therapies.
• Discusses the potential of HPV-specific immunotherapies for improving patient outcomes in HNSCC.